The new agreement amends a deal reached in October to partially fund its acquisition of some Alere businesses. That agreement was for $270 million.
NeoGenomics has now redeemed 100 percent of the $110 million preferred stock issues in conjunction with the Clarient acquisition, at a cost of $105 million.
The company will use a portion of the credit facility to fund its announced acquisition of Integrated DNA Technologies.
The company immediately borrowed $255 million to pay part of the $680 million price tag for Alere's MeterPro cardiovascular and toxicology business and its BNP assay business.
The firm said that it expects to use the proceeds of the senior notes offering to contribute to retirement of remaining convertible notes.
The company amended and restated an existing senior revolving credit facility in the principal amount of $1.0 billion with the ability to increase it by up to $350 million.
Castle will use the proceeds to accelerate marketing and new product development related to its molecular prognostic tests for patients with underserved cancers.
The infectious disease diagnostics firm will initially receive $40 million from CRG, most of which will go towards paying down existing debt.
The company borrowed $205 million in revolving loans from the credit facility, which matures on December 23, 2021.
The firm did not disclose how it intended to use the $8 million, but said that it would provide temporary working capital.